{"organizations": [], "uuid": "fdc303b932be41ef0d828a01418b32531fd000c2", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180516.html", "section_title": "Archive News &amp; Video for Wednesday, 16 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-fda-accepts-turnstone-biologics-in/brief-fda-accepts-turnstone-biologics-ind-for-cancer-immunotherapy-idUSASC0A2KI", "country": "US", "domain_rank": 408, "title": "BRIEF-FDA Accepts Turnstone Biologics' IND For Cancer Immunotherapy", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.994, "site_type": "news", "published": "2018-05-16T19:47:00.000+03:00", "replies_count": 0, "uuid": "fdc303b932be41ef0d828a01418b32531fd000c2"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-fda-accepts-turnstone-biologics-in/brief-fda-accepts-turnstone-biologics-ind-for-cancer-immunotherapy-idUSASC0A2KI", "ord_in_thread": 0, "title": "BRIEF-FDA Accepts Turnstone Biologics' IND For Cancer Immunotherapy", "locations": [], "entities": {"persons": [{"name": "f. hoffmann-la roche", "sentiment": "none"}, {"name": "roche", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "turnstone biologics", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 16 (Reuters) - Turnstone Biologics:\n* TURNSTONE BIOLOGICS ANNOUNCES U.S. FDA ACCEPTANCE OF IND FOR IMMUNOTHERAPY TARGETING HPV POSITIVE CANCERS\n* TURNSTONE BIOLOGICS ANNOUNCES U.S. FDA ACCEPTANCE OF IND FOR IMMUNOTHERAPY TARGETING HPV POSITIVE CANCERS\n* TURNSTONE BIOLOGICS - ENTERED INTO A CLINICAL SUPPLY AGREEMENT WITH F. HOFFMANN-LA ROCHE LTD UNDER WHICH ROCHE WILL PROVIDE ATEZOLIZUMAB (TECENTRIQ) Source text for Eikon:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-16T19:47:00.000+03:00", "crawled": "2018-05-17T14:51:38.007+03:00", "highlightTitle": ""}